Regeneron Pharmaceuticals, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (83)

View All

Latest Posts

About This Stock More About This Stock
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
Article By: Vision And Value
Thursday, February 22, 2024 6:15 AM EDT
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
In this article: MAIA Also: LLY, MRK, NVS, ALPMY, BAYRY, GERN, REGN, TEVA, KURA, IOVA, ZNTL
Read
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
Article By: Rod Raynovich
Monday, January 22, 2024 6:15 PM EDT
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.
In this article: QQQ, IHI, XBI Also: LLY, MRK, UNH, REGN, GILD, VRTX, IHF, SPY, XLF, XLK, ABBV
Read
Visualized: The Top S&P 500 Stocks Over 20 Years
Article By: Jeff Desjardins
Wednesday, December 27, 2023 4:45 AM EDT
The top S&P 500 stocks over the last two decades
In this article: AAPL, SPX, NVDA, MNST, ISRG, BKNG, NFLX, REGN, AMZN
Read
Biotech Is Coming Back, Can The Run Last?
Article By: Rod Raynovich
Monday, December 11, 2023 7:39 PM EDT
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally.
In this article: IBB Also: LLY, MRK, REGN, BIIB, VRTX, ABBV, TWST, TXG
Read
Biotech And Healthcare Portfolio Playbook For December 2023/24
Article By: Rod Raynovich
Monday, November 27, 2023 12:47 PM EDT
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January.
In this article: IBB, VRTX, XBI Also: LLY, PFE, ISRG, XLV, ABBV, MRK, REGN
Read
All Posts

Latest Tweets for $REGN

No tweets yet!

PARTNER HEADLINES

$REGN

Comments Status Updates
Regeneron Pharmaceuticals’ Dupixent Has Multi-Billion-Dollar Potential: Polen Capital
David J. Tanner • 1/31/2018 3:55:05 AM

Note it has only been approved in Japan. And only for those whom existing treatments are ineffective. So that's a MUCH smaller market. How small I don't know. But not enough to make me bite. $REGN

1 to 1 of 1 comments